NY-MHW-LTD
16.11.2021 16:02:11 CET | Business Wire | Press release
MHW, Ltd., the leading service provider for wine, spirits, beer and cider in the United States, has announce the successful acquisition of two nationally licensed importation companies, USA Wine West and USA Wine Imports, each of whom have decades of experience in fine wine distribution, logistics management, market strategy, compliance and administration.
“Over the last 25 years, USA Wine West has provided unparalleled logistics, compliance and administrative import services to foreign and domestic wineries who launch in the U.S.,” says Founder Steve Melchiskey, who will continue leading the USA Wine West team and join MHW as Vice President of Sales and Development. “Becoming a part of MHW enables us to carry on that mission with greater resources and capabilities. This is especially exciting for the passionate wineries and individuals we work with, as well as our world-class team who has been critical to this success.”
MHW, USA Wine West and USA Wine Imports will continue to service their respective client portfolios while they explore additional ways to deliver value through their partnership with clients over time by expanding on service capabilities, such as global consolidated logistics and more comprehensive direct-to-retail offerings.
“MHW is thrilled to welcome USA Wine West and USA Wine Imports to our team,” says MHW Chief Executive Officer Gabe Barkley. “Both companies enhance our leadership in serving the needs of the global fine wine market across all segments. We share a common DNA of building and valuing lasting client relationships. That orientation toward partnership is vital to our ongoing success. Because my career began in fine wine retail, I am personally thrilled about our expanded ability to help wine producers – from family-owned wineries to private-label programs – establish their presence in the U.S. market alongside our existing leadership positions in spirits and malt beverages.”
“It has been gratifying and humbling to have presided over a period of incredible growth at USA Wine Imports and we are very excited to be passing the baton to such a capable partner in MHW,” says former USA Wine Imports Vice President Nicolas Mestre. “This partnership will allow our portfolios the additional resources they require to scale and thrive in the market.” Sandi Bartel, USA Wine’s longtime General Manager, will continue to manage day-to-day operations.
About MHW, LTD.
MHW, LTD . is the leading beverage alcohol service partner in the United States, European Union and United Kingdom, specializing in strategic, scalable back-office solutions including compliance management, licensing, operations, logistics, fulfillment, accounting, business insight reporting, and technology. Since 1995, MHW has served as the national importer and distributor to international brands of all sizes, helping more than 100,000 wine, spirits and beer products successfully enter the U.S. MHW’s global wholesale capabilities give clients access to the retail trade in four key U.S. markets, the EU and UK. Companies who partner with MHW have the competitive advantage to focus time and effort on building brand sales. With strategic and attentive teams who have decades of back-office beverage alcohol experience, MHW offers unparalleled expertise and service excellence. To learn how to make your mark in the US and EU, please visit mhwltd.com .
About USA Wine West
USA Wine West is a premier provider of national wine import services in the U.S. A fully licensed federal importer, they work in partnership with the sales and marketing teams of foreign and domestic wineries to distribute wine to wholesalers in all 50 states. They work strategically with client portfolios to provide a cost-effective, integrated sales platform, along with an efficient logistical and compliance system designed to support foreign wineries to succeed in this competitive market.
About USA Wine Imports
USA Wine Imports is a national importer of wine and spirits providing wholesale customers distribution in all major wine markets in the U.S. USA Wine Imports works closely with wine and spirits producers, importers, brokers and agents to develop innovative sales and marketing strategies and meet ambitious sales goals in a crowded marketplace. In addition, they handle import, freight, compliance, licensing, warehousing, order fulfillment, invoicing, inventory control and accounting services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005452/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
